Compound News and Research

RSS

New vaccine to prevent malaria infection shown promise to protect young children

A new vaccine to prevent the deadly malaria infection has shown promise to protect the most vulnerable patients - young children - against the disease, according to an international team of researchers led by the University of Maryland School of Medicine's Center for Vaccine Development (CVD) and the Malaria Research and Training Center at the University of Bamako in Mali, West Africa.

4 Feb 2010

Phase 2a clinical trial results of VX-809 in patients with CF announced

Vertex Pharmaceuticals Incorporated today announced results from a preliminary analysis of data from a 28-day Phase 2a clinical trial of VX-809 in patients with cystic fibrosis (CF) who are homozygous for the F508del mutation.

4 Feb 2010

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Arrowhead Research Corporation today announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope’s lead compound for cartilage regeneration. The study’s authors, which include Nanotope co-founder Dr. Samuel Stupp, showed that Nanotope’s bioactive nanofiber system promotes the growth of new cartilage in a rabbit model. The treatment is engineered to repair cartilage defects by working with an animal’s own bone marrow stem cells to stimulate the production of new natural cartilage.

3 Feb 2010

Nanotope publishes preclinical data demonstrating cartilage regeneration

Arrowhead Research Corporation has announced publication in Proceedings of the National Academy of Sciences (PNAS) of a study using Nanotope's lead compound for cartilage regeneration.

3 Feb 2010

New formulated soy product offers heart health benefits

Just in time for Heart Health Month, EcoNugenics introduces the newest in their scientifically formulated product line: CIRCUTOL™ Cardiovascular Health Support.

2 Feb 2010

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs targeting large, underserved medical markets, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia.

2 Feb 2010

Cytheris broadens patent protection for recombinant human interleukin-7

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO’s official communication that the Company’s application has successfully completed examination and that a patent will be issued.

2 Feb 2010

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.

2 Feb 2010

Scientists and engineers conduct research on environmental health impacts of nanomaterials

As researchers around the world hasten to employ nanotechnology to improve production methods for applications that range from manufacturing materials to creating new pharmaceutical drugs, a separate but equally compelling challenge exists.

2 Feb 2010

Depomed expands patent portfolio around extended release gabapentin formulation technology

Depomed, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a U.S. patent application (No. 12/239,591) directed to pharmaceutical dosage forms that deliver the compound gabapentin via Depomed’s proprietary Acuform® gastric retentive drug delivery technology.

2 Feb 2010

Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C

The development of antibiotics gave physicians seemingly miraculous weapons against infectious disease. Effective cures for terrible afflictions like pneumonia, syphilis and tuberculosis were suddenly at hand. Moreover, many of the drugs that made them possible were versatile enough to knock out a wide range of deadly bacterial threats.

2 Feb 2010

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Pervasis Therapeutics, Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration (FDA) on the design of a pivotal Phase 3 clinical trial for Vascugel®, an investigational new drug for the prevention of hemodialysis access graft failure.

2 Feb 2010

Researchers identify antiviral small molecule that is effective against numerous viruses

Viruses are insidious creatures. They differ from each other in many ways, and they can mutate - at times seemingly at will, as with HIV - to resist a host of weapons fired at them. Complicating matters further is that new viruses are constantly emerging.

2 Feb 2010

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

TOPICA Pharmaceuticals, a privately-held biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's Investigational New Drug (IND) application for the use of luliconazole, its lead product candidate, in patients with onychomycosis (nail and nail bed fungal infections).

1 Feb 2010

Cephalon to acquire Swiss-based pharmaceutical company

Cephalon, Inc. (Nasdaq: CEPH) announced today that it has signed an agreement to acquire Mepha AG and its subsidiaries, a profitable, privately-held, Swiss-based pharmaceutical company.

1 Feb 2010

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Abbott announced today an exclusive worldwide licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, a pre-clinical monoclonal antibody identified at the Centre d'Immunologie Pierre Fabre (CIPF) in France and targeting the cMet receptor for the treatment of cancer.

1 Feb 2010

Structure and activities to drive growth and profitability during pharmaceutical new product planning

With the prospect of health-care reform still looming, pharmaceutical and biotech companies face tremendous pressure to keep the costs of their products down.

30 Jan 2010

USP develops revised quality guidelines for pharmacists who prepare life-saving drugs

To further protect the safety of patients taking individually prepared medications, the U.S. Pharmacopeial Convention (USP) has developed new and revised quality guidelines for pharmacists who compound-or individually prepare-these life-saving drugs.

30 Jan 2010

$Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia$

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrinology, today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of perifosine (KRX-0401) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of the Journal of Clinical Cancer Research.

30 Jan 2010

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Diffusion Pharmaceuticals LLC, a clinical-stage drug-development company commercializing first-in-class drugs to treat serious or life-threatening unmet medical conditions, today announced that it closed on $5.9 million in additional private financing during the second half of 2009, bringing the total the company raised in 2009 to $7.1 million.

29 Jan 2010

Compound News and Research

New vaccine to prevent malaria infection shown promise to protect young children

Phase 2a clinical trial results of VX-809 in patients with CF announced

Nanotope’s bioactive nanofiber system promotes cartilage regeneration

Nanotope publishes preclinical data demonstrating cartilage regeneration

New formulated soy product offers heart health benefits

Vantia Therapeutics initiates Phase IIb trial of VA106483 for nocturia

Cytheris broadens patent protection for recombinant human interleukin-7

Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S

Scientists and engineers conduct research on environmental health impacts of nanomaterials

Depomed expands patent portfolio around extended release gabapentin formulation technology

Study shows antiviral drugs could offer protection against HIV, Ebola, herpes and hepatitis C

Pervasis Therapeutics reaches agreement with FDA on pivotal Phase 3 clinical trial for Vascugel

Researchers identify antiviral small molecule that is effective against numerous viruses

TOPICA's IND for onychomycosis antifungal agent accepted by FDA

Cephalon to acquire Swiss-based pharmaceutical company

Abbott signs licensing agreement with Pierre Fabre SA to develop and commercialize cancer antibody h224G11

Structure and activities to drive growth and profitability during pharmaceutical new product planning

USP develops revised quality guidelines for pharmacists who prepare life-saving drugs

Perifosine holds promise as a single agent for relapsed/refractory Waldenstrom's Macroglobulinemia

Diffusion Pharmaceuticals closes on $5.9M in additional private financing

Enhancing confidence in chemical ionization spectrometry data eBook

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence

Bringing real-time analytics to downstream bioprocess monitoring

Latest News